Drug intelligence / Profile preview

MB-002

Development stage: Phase 2
Lead developer: SCM Lifescience
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics

Overview

MB-002 is an unselected, autologous, amplified tumor total RNA-transfected dendritic cell vaccine. It is used as a vaccine modality and is being developed by Argos. The primary indication is for renal cell carcinoma, where it has reached Phase 2 clinical trials.

Other names: autologous dendritic cell immunotherapy

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on MB-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-002.

Explore the full profile